Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1986-9-29
pubmed:abstractText
Liver oxidative metabolism, assessed by debrisoquine hydroxylation test, was studied in 107 healthy volunteers and in 71 patients with or without neuroleptic drug treatment. The mean metabolic ratio (MR = debrisoquine/4-hydroxydebrisoquine excretion in the urine) was 2.8 +/- 0.1 (s.e. mean) in the control group, six persons being poor metabolizers of debrisoquine (MR greater than or equal to 12.6). The mean MR (12.1 +/- 1.5) was significantly higher in those 42 patients taking neuroleptics than in patients without neuroleptics (0.8 +/- 0.1). In the former group, seventeen patients had a MR exceeding 12.6. Oral contraceptives, antiepileptics, benzodiazepines and progestin derivates did not increase MR values, the highest individual ratio being 2.72 in those subjects not receiving neuroleptics. These results suggest a probable competitive inhibition of oxidative metabolism by neuroleptics. This is a phenomenon of potential clinical importance both in patients with an inherited poor metabolic capacity and in patients receiving other drugs like beta-adrenoceptor blocking agents and tricyclic antidepressants oxidized by the same enzyme system.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-151576, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-4015690, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-4027138, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-499318, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-6106391, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-6107617, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-6111662, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-6120324, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-6488689, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-6827912, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-6906263, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-7042170, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-7083735, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-7124987, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-71400, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-7318304, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-7371707, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-7381862, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-7387339, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-7442467, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-758241, http://linkedlifedata.com/resource/pubmed/commentcorrection/2874826-838796
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
89-92
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Inhibitory effects of neuroleptics on debrisoquine oxidation in man.
pubmed:publicationType
Journal Article